Inventiva Financials - Benzinga

Inventiva SA

IVANASDAQ

Trade with Public

Trade with Public

$4.63

-0.07-1.49%

Last update: Aug 18, 3:40 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Options Stock Report

Inventiva Financials

Inventiva (IVA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Inventiva Reports No Revenue During H1, Compared To €4.5M YoY

Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic

Benzinga Newsdesk

PRO
Inventiva FY EPS $(2.14) Misses $(1.66) Estimate, Sales $5.064M Miss $6.000M Estimate

Inventiva (NASDAQ:IVA) reported quarterly losses of $(2.14) per share which missed the analyst consensus estimate of $(1.66) by 28.92 percent. This is a 35.74 percent increase over losses of $(3.33) per share from the

Benzinga Newsdesk

Earnings Scheduled For March 30, 2026

Benzinga Insights

Earnings Scheduled For September 29, 2025

Companies Reporting Before The Bell • Inventiva (NASDAQ: IVA) is projected to report quarterly loss at $0.41 per share on revenue of $5.31 million. • Uxin (NASDAQ: UXIN) is estimated to report earnings for its second quarter.

Benzinga Insights

PRO
Inventiva H1 EPS $(1.84) Misses $(0.41) Estimate, Sales $5.050M Miss $5.310M Estimate

Inventiva (NASDAQ: IVA) reported quarterly losses of $(1.84) per share which missed the analyst consensus estimate of $(0.41) by 348.05 percent. This is a 81.88 percent decrease over losses of $(1.01) per share from the same period last year.

Benzinga Newsdesk

Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings

Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept. 29.

Avi Kapoor